Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.41 |
| ▸ | MMP3 | P08254 | 12/20 | 0.41 |
| ▸ | MMP1 | P03956 | 10/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075177 | 1.00 | MMP2 (0.41) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL8055024 | 0.76 | CTSK (0.44) | MMP2MMP3MMP1 | |
| SCHEMBL5435586 | 0.73 | MEN1 (0.44) | — | |
| SCHEMBL6159691 | 0.72 | CTSK (0.45) | — | |
| SCHEMBL8055025 | 0.71 | MMP2 (0.77) | MMP2MMP3MMP1MMP9MMP7 | |
| SCHEMBL8221381 | 0.71 | ALDH1A1 (0.44) | — | |
| SCHEMBL8221385 | 0.71 | ALDH1A1 (0.44) | — | |
| SCHEMBL8218717 | 0.71 | ALDH1A1 (0.44) | — | |
| SCHEMBL8218720 | 0.71 | ALDH1A1 (0.44) | — | |
| SCHEMBL8218572 | 0.71 | ALDH1A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225272-A1 | Novel mmp-2/mmp-9 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-12-04 | — | — | US | disclosed |
| WO-2001026671-A1 | METHODS OF TREATMENT USING DUAL MATRIX-METALLOPROTEINASE-2 AND MATRIX METALLOPROTEINASE-9 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225272-A1 | Novel mmp-2/mmp-9 inhibitors | MMP9, MMP10, MMP3 | MMP2 4/4885MMP3 3/4885MMP1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.